Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study (Q38855950)
Jump to navigation
Jump to search
scientific article published on 4 April 2017
Language | Label | Description | Also known as |
---|---|---|---|
English | Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study |
scientific article published on 4 April 2017 |
Statements
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study (English)
1 reference
Andrea B Apolo
Jeffrey R Infante
Ani Balmanoukian
Manish R Patel
Ding Wang
Anthony E Mega
Carolyn D Britten
Alain C Mita
Howard Safran
Thomas E Stinchcombe
Marko Srdanov
Arnold B Gelb
Michael Schlichting
Kevin Chin
4 April 2017
1 reference
1 reference